Starting from evidence based on the active role of Gal-3 in the modulation of cardiac fibrosis, multiple research articles have proposed this molecule as a biomarker for various cardiovascular diseases, including cardiac insufficiency, atrial fibrillation and congenital cardiac malformations, or as a predictor of long-term outcomes after cardiac resynchronization therapy [27,28,29,30,31]. The gene discussed is LGALS3; the disease is heart failure.